News

Theratechnologies FDA Rejection

1 Mins read

Theratechnologies is poised for a significant setback as the Food and Drug Administration (FDA) has rejected its supplemental biologics license application for an intramuscular method of administering a maintenance dose of Trogarzo, an HIV-1 inhibitor.

Stock Performance

In premarket trading on Nasdaq, Theratechnologies shares were down by 30%, following a 1.2% increase in 2024, closing at $1.64 in the previous session. Similarly, in Toronto, the shares closed at C$2.20, reflecting a 2.8% gain in the new year.

FDA’s Decision

The biopharmaceutical company received a refusal to file letter from the FDA regarding its supplemental license application. The FDA cited that the application lacked completeness for a substantive review. Particularly, it mentioned the absence of essential data required to establish the pharmacokinetic bridge between the intramuscular and intravenous infusion route of administration of Trogarzo.

Company Response

Commenting on the FDA’s decision, Christian Marsolais, Theratechnologies’ chief medical officer, expressed disappointment but acknowledged the challenges based on the TMB-302 study results from October 2023. He stated, “We will now assess our options regarding this application.”

Theratechnologies now faces uncertainties concerning the future of its sBLA for Trogarzo’s intramuscular administration.

Related posts
News

FioBit's Ultimate Dogecoin Cloud Mining Guide for 2025: Secure DOGE Investment Without Hardware Using the Most Trusted Crypto Mining Provider to Hedge Against Bitcoin Drops | Business Upturn

2 Mins read
Sydney, Australia , May 08, 2025 (GLOBE NEWSWIRE) — As Bitcoin continues to experience short-term volatility in 2025, a growing number of…
News

Analysts see Bitcoin at $100,000 soon

2 Mins read
Crypto analysts expect Bitcoin to soar to US$100,000, even if the Federal Open Market Committee (FOMC) keeps interest rates unchanged at its…
News

Spartan Delta Corp. Announces First Quarter 2025 Results

13 Mins read
Selected financial and operational information is set out below and should be read in conjunction with Spartan’s unaudited interim financial statements and…

Leave a Reply

Your email address will not be published. Required fields are marked *

46 − 37 =